A recent report highlights that biosimilars approved by FDA have generated over $56 billion in savings since 2015, yet their market adoption remains uneven across therapeutic areas. Pharmacy benefit managers (PBMs) often favor pricier brand-name biologics over available, less expensive biosimilars, hampering competition and patient access. Compounding this, a scarcity of biosimilar candidates for many biologics nearing patent expiration threatens future cost reductions and broader adoption of these lower-cost alternatives.